160 related articles for article (PubMed ID: 20855828)
21. Effect of age on systemic exposure and haematological toxicity of carboplatin in advanced non-small cell lung cancer patients.
Merino-Sanjuán M; Monteiro JF; Porta-Oltra B; Maestu I; Almenar D; Jiménez-Torres NV
Basic Clin Pharmacol Toxicol; 2011 Dec; 109(6):457-64. PubMed ID: 21726412
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin.
Zandvliet AS; Schellens JH; Dittrich C; Wanders J; Beijnen JH; Huitema AD
Br J Clin Pharmacol; 2008 Oct; 66(4):485-97. PubMed ID: 18637887
[TBL] [Abstract][Full Text] [Related]
23. Clinical pharmacokinetics and dose optimisation of carboplatin.
Duffull SB; Robinson BA
Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
[TBL] [Abstract][Full Text] [Related]
24. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
25. Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
Rajkumar SV; Frytak S; Rubin J; Camoriano JK; Fitch TR
Am J Clin Oncol; 1997 Oct; 20(5):500-4. PubMed ID: 9345336
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.
Gajra A; Mehdi SA; Kirshner J; Newman N; Graziano SL
Lung Cancer; 2001 May; 32(2):189-96. PubMed ID: 11325490
[TBL] [Abstract][Full Text] [Related]
27. [Carboplatin plus gemcitabine therapy versus carboplatin plus weekly paclitaxel therapy for advanced non-small cell lung cancer].
Sumiyoshi H; Yamasaki M; Doi M; Maeda H; Kuwabara M; Miyamoto S; Fukuhara K
Gan To Kagaku Ryoho; 2006 Jun; 33(6):773-7. PubMed ID: 16770095
[TBL] [Abstract][Full Text] [Related]
28. Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combination.
Leong SS; Wee J; Tay MH; Toh CK; Tan SB; Thng CH; Foo KF; Lim WT; Tan T; Tan EH
Cancer; 2005 Feb; 103(3):569-75. PubMed ID: 15611975
[TBL] [Abstract][Full Text] [Related]
29. A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
Schallier D; Neyns B; Fontaine C; Steene JV; De Mey J; Meysman M; De Grève J
Lung Cancer; 2007 May; 56(2):247-54. PubMed ID: 17337086
[TBL] [Abstract][Full Text] [Related]
30. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-26-S15-29. PubMed ID: 9346218
[TBL] [Abstract][Full Text] [Related]
31. Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study.
Mäenpää JU; Grénman SE; Jalkanen JT; Kuoppala TA; Leminen AO; Puistola US; Vuolo-Merilä PM; Yliskoski MH
Gynecol Oncol; 2006 Apr; 101(1):114-9. PubMed ID: 16266743
[TBL] [Abstract][Full Text] [Related]
32. A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder.
Grivas PD; Hussain M; Hafez K; Daignault-Newton S; Wood D; Lee CT; Weizer A; Montie JE; Hollenbeck B; Montgomery JS; Alva A; Smith DC
Urology; 2013 Jul; 82(1):111-7. PubMed ID: 23706253
[TBL] [Abstract][Full Text] [Related]
33. A phase I report of paclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma.
Dunphy FR; Boyd JH; Kim HJ; Dunphy CH; Harrison BR; Dunleavy TL; Rodriguez JJ; McDonough EM; Minster JR; Hilton JG
Cancer; 1997 May; 79(10):2016-23. PubMed ID: 9149030
[TBL] [Abstract][Full Text] [Related]
34. Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer.
Micha JP; Goldstein BH; Mattison JA; Bader K; Graham C; Rettenmaier MA; Brown JV; Markman M
Gynecol Oncol; 2005 Jan; 96(1):132-5. PubMed ID: 15589591
[TBL] [Abstract][Full Text] [Related]
35. Dose intense triplet chemotherapy with gemcitabine, carboplatin, paclitaxel with peripheral blood progenitor cell support for six cycles in advanced epithelial ovarian cancer.
Barlow C; Nystrom M; Oesterling C; Fennell D; Ismay J; Gallagher C
Br J Cancer; 2004 Apr; 90(7):1318-22. PubMed ID: 15054448
[TBL] [Abstract][Full Text] [Related]
36. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
37. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP
Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572
[TBL] [Abstract][Full Text] [Related]
38. Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study.
Papadimitriou CA; Fountzilas G; Aravantinos G; Kalofonos C; Moulopoulos LA; Briassoulis E; Gika D; Dimopoulos MA;
Gynecol Oncol; 2004 Jan; 92(1):152-9. PubMed ID: 14751151
[TBL] [Abstract][Full Text] [Related]
39. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
[TBL] [Abstract][Full Text] [Related]
40. Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer.
Iaffaioli RV; Tortoriello A; Facchini G; Caponigro F; Gentile M; Marzano N; Gravina A; Dimitri P; Costagliola G; Ferraro A; Ferrante G; De Marino V; Illiano A
J Clin Oncol; 1999 Mar; 17(3):921-6. PubMed ID: 10071285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
